Buthionine sulfoximine
Appearance
![]() | |
![]() | |
Names | |
---|---|
IUPAC name
2-amino-4-(butylsulfonimidoyl)butanoic acid
| |
Other names
BSO
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.156.351 |
MeSH | Buthionine+sulfoximine |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C8H18N2O3S | |
Molar mass | 222.305 g/mol |
Density | 1.29 g/mL |
Melting point | 215 °C (419 °F; 488 K) |
Boiling point | 382.3 °C (720.1 °F; 655.5 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Buthionine sulfoximine (BSO) is a sulfoximine which reduces levels of glutathione and is being investigated as an adjunct with chemotherapy in the treatment of cancer.[1] The compound inhibits gamma-glutamylcysteine synthetase, the enzyme required in the first step of glutathione synthesis. Buthionine sulfoximine may also be used to increase the sensitivity of parasites to oxidative antiparasitic drugs.[2]
References
- ^ Defty, CL; Marsden, JR (2012). "Melphalan in regional chemotherapy for locally recurrent metastatic melanoma". Current Topics in Medicinal Chemistry. 12 (1): 53–60. doi:10.2174/156802612798919187. PMID 22196271.
- ^ "Definition of buthionine sulfoximine - National Cancer Institute Drug Dictionary". 2011-02-02.